Table 2.

Demographic and clinical characteristics by inhibitor status among 6624 persons with NSHA in the United States, 2010-2018

CharacteristicsNoninhibitor (n = 6453)*Inhibitor (n = 171)*P
Year of birth 1994 (1974-2004) 1991 (1971-2000)  
Age, y    
 At start of observation period 19 (8-39) 21 (11-41)  
 At end of follow-up or death 25 (14-44) 27 (18-47)  
Sex    
 Female 927 (14.4) 1 (0.6) <.001 
 Male 5524 (85.6) 170 (99.4)  
Race    
 White 5367 (83.2) 132 (77.2) <.001 
 Black 512 (7.9) 31 (18.1)  
 Other/unknown 574 (8.9) 8 (4.7)  
Ethnicity    
 Hispanic 1182 (18.3) 17 (9.9) .013 
 Non-Hispanic 5192 (80.5) 153 (89.5)  
 Unknown 79 (1.2) 1 (0.6)  
Severity    
 Mild 4640 (71.9) 80 (46.8) <.001 
 Moderate 1813 (28.1) 91 (53.2)  
FVIII exposure    
 Yes 4957 (76.8) 165 (96.5) <.001 
 No 551 (8.5) 4 (2.3)  
 Unknown 945 (14.3) 2 (1.2)  
Infections    
 Hepatitis B 102 (1.6) 3 (1.8) NS 
 Hepatitis C 596 (9.2) 27 (15.8) .004 
 HIV 166 (2.6) 4 (2.3) NS 
CharacteristicsNoninhibitor (n = 6453)*Inhibitor (n = 171)*P
Year of birth 1994 (1974-2004) 1991 (1971-2000)  
Age, y    
 At start of observation period 19 (8-39) 21 (11-41)  
 At end of follow-up or death 25 (14-44) 27 (18-47)  
Sex    
 Female 927 (14.4) 1 (0.6) <.001 
 Male 5524 (85.6) 170 (99.4)  
Race    
 White 5367 (83.2) 132 (77.2) <.001 
 Black 512 (7.9) 31 (18.1)  
 Other/unknown 574 (8.9) 8 (4.7)  
Ethnicity    
 Hispanic 1182 (18.3) 17 (9.9) .013 
 Non-Hispanic 5192 (80.5) 153 (89.5)  
 Unknown 79 (1.2) 1 (0.6)  
Severity    
 Mild 4640 (71.9) 80 (46.8) <.001 
 Moderate 1813 (28.1) 91 (53.2)  
FVIII exposure    
 Yes 4957 (76.8) 165 (96.5) <.001 
 No 551 (8.5) 4 (2.3)  
 Unknown 945 (14.3) 2 (1.2)  
Infections    
 Hepatitis B 102 (1.6) 3 (1.8) NS 
 Hepatitis C 596 (9.2) 27 (15.8) .004 
 HIV 166 (2.6) 4 (2.3) NS 

NS, not significant.

*

Data presented are medians (interquartile range) or numbers (percentages). Categorical variables were analyzed with χ2 test or Fisher’s exact test, as appropriate.

or Create an Account

Close Modal
Close Modal